Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-17-006208
Filing Date
2017-08-08
Accepted
2017-08-08 07:44:00
Documents
57
Period of Report
2017-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q vygr-20170630x10q.htm 10-Q 1507760
2 EX-31.1 vygr-20170630ex311dd7f7f.htm EX-31.1 20017
3 EX-31.2 vygr-20170630ex312ef7883.htm EX-31.2 19996
4 EX-32.1 vygr-20170630ex321780481.htm EX-32.1 15345
5 GRAPHIC vygr20170630x10q001.jpg GRAPHIC 86840
  Complete submission text file 0001558370-17-006208.txt   6141980

Data Files

Seq Description Document Type Size
6 EX-101.INS vygr-20170630.xml EX-101.INS 1322740
7 EX-101.SCH vygr-20170630.xsd EX-101.SCH 44943
8 EX-101.CAL vygr-20170630_cal.xml EX-101.CAL 49893
9 EX-101.DEF vygr-20170630_def.xml EX-101.DEF 169674
10 EX-101.LAB vygr-20170630_lab.xml EX-101.LAB 380898
11 EX-101.PRE vygr-20170630_pre.xml EX-101.PRE 294517
Mailing Address 75 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 75 SIDNEY STREET CAMBRIDGE MA 02139 857-259-5340
Voyager Therapeutics, Inc. (Filer) CIK: 0001640266 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37625 | Film No.: 171013258
SIC: 2836 Biological Products, (No Diagnostic Substances)